Salvianolate Reduces Glucose Metabolism Disorders in Dimethylnitrosamine-Induced Cirrhotic Rats  

作　　者：TANG Li-rui TAO Yan-yan LIU Cheng-hai WANG Hai-nan 

机构地区：[1]Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 2201203, China [2]Department of Emergency Medicine, Putuo Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 2200062, China [3]Shanghai Key Laboratory of Traditional Chinese Medicine, Shanghai 2201203, China [4]E-Institute of Traditional Chinese Medicine Internal Medicine, Shanghai Municipal Education Commission, Shanghai 2201203, China [5]China Food and Drug Administration, Beijing 2100053, China

出　　处：《Chinese Journal of Integrative Medicine》2018年第9期661-669,共9页中国结合医学杂志（英文版）

基　　金：Supported by the National Science and Technology Major Project(No.2014ZX10005001);the International S&T Cooperation Program of China(No.2014DFA31440);"Three Year Action Plan" for Development of Traditional Chinese Medicine in Shanghai(No.ZY3CCCX-2-1003);Shanghai Clinical Key Laboratory of Traditional Chinese Medicine(No.14DZ2273200)

摘　　要：Objective： To evaluate the preventive effect of salvianolate （Sal B） on glucose metabolism disorders of dimethylnitrosamine （DMN）-induced cirrhotic rats. Methods： Fiffy-five Wistar rats were randomly divided into a control group （n=10） and a cirrhotic group （n=45） according to a random number table. Liver cirrhosis was induced by intraperitoneal administration of DMN. The cirrhotic rats were divided into model, Sal B and metformin groups （n=15）, respectively. Rats in the model group were given saline, two treatment groups were given Sal B （50 mg/kg）, metformin （150 mg/kg） respectively for 28 consecutive days, while rats in the control group were injected 0.9% saline with same volume of vehicle. Body weight was measured everyday. Insulin sensitivity was determined by euglycemic hyperinsulinemic clamp. Organ index, glucose tolerance test （OGTT）, and fasting plasma glucose （FPG）, fasting insulin （FINS）, hepatic glycogen, hydroxyproline （HYP） and liver function were detected at the end of the treatment. Area under the curve （AUC） for OG3-1 was calculated. Liver and pancreas histology were determined by histopathological examination with hematoxylin and eosin staining （HE）, Sirius Red staining and Masson＇s trichrome staining, respectively. Hepatic expression of α-smooth muscle actin （oL-SMA） and collagen （Col I ） were evaluated by immunohistochemical staining. Results： Compared with the model group, Sal B significantly increased body and liver weight, liver-body ratio, glucose infusion rate （GIR）, FPG, FINS levels and hepatic glycogen at the end of administration （P〈0.05 or P〈0.01）. Meanwhile, Sal B significantly decreased AUC for OGI-I＇, spleen weight, spleen-body ratio, aminotransferase and HYP level （P〈0.05 or P〈0.01）. Sal B was also effective in alleviating necrosis of liver tissue, suppressing fibrosis progression and inhibiting the expression of oL-SMA and Col I in liver. Compared with the metformin group, Sal B had advantObjective： To evaluate the preventive effect of salvianolate （Sal B） on glucose metabolism disorders of dimethylnitrosamine （DMN）-induced cirrhotic rats. Methods： Fiffy-five Wistar rats were randomly divided into a control group （n=10） and a cirrhotic group （n=45） according to a random number table. Liver cirrhosis was induced by intraperitoneal administration of DMN. The cirrhotic rats were divided into model, Sal B and metformin groups （n=15）, respectively. Rats in the model group were given saline, two treatment groups were given Sal B （50 mg/kg）, metformin （150 mg/kg） respectively for 28 consecutive days, while rats in the control group were injected 0.9% saline with same volume of vehicle. Body weight was measured everyday. Insulin sensitivity was determined by euglycemic hyperinsulinemic clamp. Organ index, glucose tolerance test （OGTT）, and fasting plasma glucose （FPG）, fasting insulin （FINS）, hepatic glycogen, hydroxyproline （HYP） and liver function were detected at the end of the treatment. Area under the curve （AUC） for OG3-1 was calculated. Liver and pancreas histology were determined by histopathological examination with hematoxylin and eosin staining （HE）, Sirius Red staining and Masson＇s trichrome staining, respectively. Hepatic expression of α-smooth muscle actin （oL-SMA） and collagen （Col I ） were evaluated by immunohistochemical staining. Results： Compared with the model group, Sal B significantly increased body and liver weight, liver-body ratio, glucose infusion rate （GIR）, FPG, FINS levels and hepatic glycogen at the end of administration （P〈0.05 or P〈0.01）. Meanwhile, Sal B significantly decreased AUC for OGI-I＇, spleen weight, spleen-body ratio, aminotransferase and HYP level （P〈0.05 or P〈0.01）. Sal B was also effective in alleviating necrosis of liver tissue, suppressing fibrosis progression and inhibiting the expression of oL-SMA and Col I in liver. Compared with the metformin group, Sal B had advant

关 键 词：SALVIANOLATE FIBROSIS cirrhosis insulin resistance GLYCOGEN METFORMIN 

分 类 号：R575.2[医药卫生—消化系统]